“ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma” (2022) Biomolecules and Biomedicine, 22(6), pp. 949–958. doi:10.17305/bjbms.2022.7268.